VivoSeq
Respiratory

COPD

14

Pipeline Programs↗

22

Active Trials↗

26

Companies Involved↗

COPD is an emerging landscape with 14 programs across 26 companies. The most active players are Johnson & Johnson, Bayer, Sanofi. 2 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

49/100

Pipeline Velocity

27/100

Mech. Concentration

14/100

Completion Rate

91/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2Bayer logo

Bayer

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 3P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 3AstraZeneca logo

AstraZeneca

6 programs

Phase 3Boehringer Ingelheim logo

Boehringer Ingelheim

2 programs

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

10 of 12 classified programs — the dominant modality here.

17%ALL OTHERSMonoclonal antibody217%

Small molecule leads; the ring shows all 12 classified programs, each share of the total. Modality classified for 81% of 16 pipeline programs.

Analysis

Trial Status

134

clinical trials

Completed91 · 68%
Unknown status11 · 8%
Recruiting11 · 8%
Not yet recruiting7 · 5%
Withdrawn5 · 4%
Active, not recruiting4 · 3%
Other5 · 4%

Clinical Trials

Trial Activity

134 trials

"The Effect of Inhaled Nitroglycerin for COPD Patients
Recruiting·—·Phase 2/3·NCT06785337·40 enrolled
Reducing Breathlessness With Dronabinol in COPD Patients
Recruiting·VVejle Hospital·Phase 3·NCT06473701·30 enrolled
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
Recruiting·UUniquity One (UNI)·Phase 2·NCT06496620·171 enrolled
Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators
Recruiting·UUniversity of Tennessee Graduate School of Medicine·Phase 4·NCT07133880·72 enrolled
The Acute Cardiorespiratory Response to Blood-flow Restricted Versus Traditional Exercise Training Regimens (CaRe BFR):4 Randomized Crossover Studies
Recruiting·UUniversity of Zurich·Preclinical·NCT05163600·24 enrolled
An Investigation of Health Literacy, Physical and Cognitive Function, Health-related Behaviors, and Quality of Life in Chronic Obstructive Pulmonary Disease and Healthy Individuals
Recruiting·HHacettepe University·N/A·NCT06497816·144 enrolled
Effect of Combined Upper and Lower Extremity Endurance Training Versus Lower Extremity Training Alone on ADL and Walking in COPD Patients
Recruiting·IIstituti Clinici Scientifici Maugeri SpA·Preclinical·NCT05708443·36 enrolled
Randomized Trial Evaluating the Rate of Pneumothorax in Severe Emphysema Secondary to Endoscopic Volume Reduction With Two-stage ZEPHYR® Valves Versus Endoscopic Volume Reduction With One-stage ZEPHYR® Valves
Recruiting·UUniversity Hospital, Limoges·Preclinical·NCT06181357·244 enrolled
Closed Loop Oxygen Control in COPD Patients Treated With Nasal High Flow in the Hospital
Recruiting·FFisher and Paykel Healthcare·Preclinical·NCT07222410·70 enrolled
Physiologic Effects of Nasal High Flow on Exercise Tolerance in Chronic Obstructive Pulmonary Disease (COPD)
Recruiting·UUniversity of Miami·Preclinical·NCT06578156·45 enrolled
DUPIXENT-COPD: Dupilumab in Type 2 COPD
Recruiting·Regeneron logoRegeneron·Phase 3·NCT04456426·935 enrolled
A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD
Active, not recruiting·AAreteia Therapeutics·Phase 2·NCT06533553·30 enrolled
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
Active, not recruiting·Sanofi logoSanofi·Phase 3·NCT06208306·700 enrolled
Michigan eArly Disease Progression Cohort in COPD (MAP COPD)
Active, not recruiting·UUniversity of Michigan·N/A·NCT04968249·200 enrolled
LIBERTY-COPD: Dupilumab in Eosinophilic COPD
Active, not recruiting·Sanofi logoSanofi·Phase 3·NCT04198129·1,100 enrolled
Page 1 of 9

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)